Anticoagulation Management of Children with Congenital Heart Disease on Extracorporeal Membrane Oxygenation – Center-Specific Experiences, Morbidities, and Mortality

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039062

Enrollment

Registered

2026-01-23

Start date

2025-11-05

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Q20-Q28

Interventions

Group 1: For coagulation management during extracorporeal membrane oxygenation (ECMO), the combined use of multiple laboratory parameters is recommended. Among other targets, an ACT of 180 - 220 secon

Eligibility

Sex/Gender

All

Age

0 Years to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: - Age 0 to = 18 years - Presence of congenital heart disease - Use of extracorporeal membrane oxygenation

Exclusion criteria

Exclusion criteria: Exclusion criteria: - Death prior to initiation of extracorporeal membrane oxygenation - Congenital coagulation disorder

Design outcomes

Primary

Measure	Time frame
Morbidity: - Surgical bleeding - Intracranial hemorrhage - Pulmonary hemorrhage - Gastrointestinal bleeding - Other ECMO-related complications: - Thoracic re-explorations while on ECMO - Exchange of ECMO components - Exchange of the ECMO machine - Other Coagulation management: - Number and volume of administered blood products - Anticoagulation dosage - Coagulation parameters (ACT, aPTT, INR, anti-Xa, antithrombin III, fibrinogen) Mortality	—

Measure

Time frame

Morbidity: - Surgical bleeding - Intracranial hemorrhage - Pulmonary hemorrhage - Gastrointestinal bleeding - Other ECMO-related complications: - Thoracic re-explorations while on ECMO - Exchange of ECMO components - Exchange of the ECMO machine - Other Coagulation management: - Number and volume of administered blood products - Anticoagulation dosage - Coagulation parameters (ACT, aPTT, INR, anti-Xa, antithrombin III, fibrinogen) Mortality

—

Countries

Germany

Contacts

Public ContactMartin Poryo

Universitätsklinikum des Saarlandes, Klinik für Pädiatrische Kardiologie

martin.poryo@uks.eu+49 6841 16 28374

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026